EMA Authorised: Zynyz (retifanlimab) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The European Medicines Agency authorised Zynyz (retifanlimab) for Merkel cell carcinoma; it has orphan medicine designation and is marketed by Incyte Bioscience…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• ZYNYZ (RETIFANLIMAB-DLWR)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Merkel Cell. MAH: Incyte Biosciences Distribution B.V.. Decision date: 05/03/2026. Orphan medicine